| Literature DB >> 30071640 |
You-Liang Hsieh1,2, Hsu-Ju Teng3,4, Yen-Hung Yeh5,6, Cheng-Hong Hsieh7, Chih-Yang Huang8,9,10.
Abstract
To investigate a high cholesterol diet in Alzheimer's disease (AD) mice, they were fed with (2% cholesterol) in five groups with a control group, AD mice group, AD mice plus Meretrix lusoria group, AD mice plus Geloina eros group, and, AD mice plus Corbicula fluminea group for three months, and treated with the fatty acid profiles of clams by gas chromatography (GC). The results showed that treatment with clams for three months reduced Fas/L and Caspase-3 in the Meretrix lusoria and Geloina eros groups, but Fas-associated death domain (FADD) and Caspase-8 were strongly reduced in the Geloina eros group. For the mitochondria-dependent apoptotic pathway, the reduction of apoptosis proteins were observed in the hearts of clams-treated AD mice. BAK and Caspase-9 was reduced in the Meretrix lusoria group, but Caspase-3 and Cytochrome-c were reduced in Geloina eros group. Enhancement of survival proteins p-AKT, p-IGF1R, p-PI3K, Bcl-XL, Bcl2, and the longevity SIRT1 signaling proteins, p-AMPK-α, SIRT1, PGC1-α, p-FOXO3 were observed in clams-treated mice and even more strongly enhanced in the Meretrix lusoria, Geloina eros and Corbicula fluminea groups. This study observed that the ingestion of clams caused a reduction of apoptosis proteins and enhancement of survival and SIRT1 signaling proteins in the hearts.Entities:
Keywords: Alzheimer’s disease; cardiovascular disease; clam; fatty acid; hypercholesterolemia
Mesh:
Substances:
Year: 2018 PMID: 30071640 PMCID: PMC6117677 DOI: 10.3390/md16080263
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Fatty acid profiles of the Meretrix lusoria extract (MLE), Geloina eros extract (GEE) and Corbicula fluminea extract (CFE).
| Fatty Acid | MLE (%) | GEE (%) | CFE (%) |
|---|---|---|---|
| Saturated fatty acid (SFA) (% of total fatty acid) | |||
| C12:0 | 0.13 ± 0.02 a | 0.21 ± 0.03 b | 0.15 ± 0.02 a |
| C14:0 | 0.75 ± 0.13 a | 1.23 ± 0.07 b | 0.95 ± 0.08 a |
| C15:0 | 1.56 ± 0.22 c | 0.53 ± 0.10 a | 0.87 ± 0.12 b |
| C16:0 | 12.31 ± 1.56 b | 7.65 ± 1.23 a | 10.56 ± 1.82 a |
| C17:0 | 6.23 ± 0.35 b | 5.76 ± 0.52 b | 3.27 ± 0.32 a |
| C18:0 | 0.21 ± 0.03 a | 0.31 ± 0.02 b | 0.39 ± 0.02 b |
| C20:0 | 1.13 ± 0.06 a | 3.25 ± 0.07 c | 2.87 ± 0.05 b |
| C23:0 | 0.22 ± 0.01 a | 0.32 ± 0.01 c | 1.35 ± 0.03 b |
| Monosaturated fatty acid (MUFA) (% of total fatty acid) | |||
| C14:1 | 0.51 ± 0.02 b | 0.36 ± 0.01 a | 1.56 ± 0.21 c |
| C15:1 | 0.62 ± 0.03 b | 0.21 ± 0.02 a | 0.73 ± 0.01 c |
| C16:1 n-7 | 3.52 ± 0.78 b | 2.36 ± 0.56 a | 4.83 ± 0.32 b |
| C17:1 | 1.23 ± 0.02 c | 0.56 ± 0.03 b | 0.39 ± 0.01 a |
| C18:1 n-11 | 2.32 ± 0.56 b | 1.21 ± 0.21 a | 3.26 ± 0.23 c |
| C18:1 n-9 | 5.13 ± 1.21 a | 6.56 ± 1.65 a | 8.59 ± 1.58 b |
| C18:1 n-7 | 1.16 ± 0.02 b | 2.22 ± 0.03 c | 0.25 ± 0.01 a |
| C20:1 n-7 | 1.33 ± 0.01 a | 2.29 ± 0.01 c | 3.48 ± 0.02 b |
| C20:1 n-9 | 1.25 ± 0.03 b | 0.65 ± 0.02 a | 2.36 ± 0.03 c |
| C20:1 n-11 | 3.65 ± 0.16 b | 2.13 ± 0.11 a | 3.24 ± 0.35 b |
| C22:1 n-9 | 0.26 ± 0.01 a | 2.11 ± 0.02 b | 0.27 ± 0.02 a |
| Polyunsaturated fatty acid (PUFA) (% of total fatty acid) | |||
| C16:3 n-3 | 1.72 ± 0.05 c | 1.21 ± 0.03 a | 1.33 ± 0.05 b |
| C18:2 n-6 | 0.21 ± 0.01 a | 0.36 ± 0.01 b | 0.22 ± 0.02 a |
| C18:3 n-3 | 3.23 ± 0.36 a | 5.63 ± 0.52 b | 3.23 ± 0.65 a |
| C18:3 n-6 | 1.26 ± 0.13 b | 0.82 ± 0.18 a | 1.12 ± 0.15 b |
| C18:4 n-3 | 1.03 ± 0.12 b | 0.75 ± 0.13 a | 1.09 ± 0.15 b |
| C20:1 n-6 | 4.93 ± 0.23 a | 6.31 ± 0.56 b | 4.56 ± 0.62 a |
| C20:3 n-6 | 1.15 ± 0.03 b | 0.53 ± 0.05 a | 2.02 ± 0.07 c |
| C20:3 n-3 | 0.88 ± 0.02 c | 0.62 ± 0.03 b | 0.21 ± 0.02 a |
| C20:4 n-6 | 6.52 ± 0.52 a | 7.53 ± 0.20 b | 5.33 ± 0.67 a |
| C20:4 n-3 | 1.22 ± 0.02 b | 0.76 ± 0.03 a | 1.53 ± 0.06 c |
| C20:5 n-3, EPA | 7.32 ± 0.58 a | 8.50 ± 0.75 b | 6.58 ± 0.23 a |
| C21:5 n-3 | 1.25 ± 0.06 b | 0.12 ± 0.02 a | 1.65 ± 0.01 c |
| C22:4 n-6 | 3.23 ± 0.05 b | 4.52 ± 0.03 c | 2.25 ± 0.03 a |
| C22:5 n-3 | 6.57 ± 0.08 c | 5.26 ± 0.07 b | 3.78 ± 0.07 a |
| C22:5 n-6 | 5.73 ± 0.05 b | 4.95 ± 0.03 a | 6.52 ± 0.06 c |
| C22:6 n-3, DHA | 10.23 ± 0.05 b | 12.21 ± 0.08 c | 9.21 ± 0.03 a |
| Sums of fatty acids | |||
| ƩSFA | 22.54 ± 1.56 b | 19.26 ± 1.52 a | 20.41 ± 1.23 a |
| ƩMUFA | 20.98 ± 2.31 a | 20.66 ± 3.68 a | 28.96 ± 2.23 b |
| ƩPUFA | 56.48 ± 3.62 b | 60.08 ± 2.35 c | 50.63 ± 2.57 a |
| Ʃn-3 | 26.13 ± 1.23 b | 35.06 ± 1.61 b | 28.61 ± 1.20 a |
| Ʃn-6 | 23.03 ± 0.51 b | 25.02 ± 0.31 c | 22.02 ± 0.22 a |
| Fatty Acid | MLE (%) | GEE (%) | CFE (%) |
| Ratios | |||
| PUFA/SFA | 2.50 ± 0.56 a | 3.12 ± 0.52 b | 2.48 ± 0.35 a |
| MUFA/SFA | 0.93 ± 0.01 a | 1.07 ± 0.02 b | 1.42 ± 0.03 c |
| DHA/EPA | 1.40 ± 0.01 a | 1.44 ± 0.02 b | 1.40 ± 0.01 a |
| n-3/n-6 | 1.13 ± 0.02 c | 1.40 ± 0.01 b | 1.30 ± 0.02 a |
| n-6/n-3 | 0.88 ± 0.02 a | 0.71 ± 0.01 b | 0.77 ± 0.01 c |
(a–c) Values represent mean ± SD (n = 3). Different lowercase letters in the same row indicate significant difference (p < 0.05). ƩSFA = saturated fatty acid; ƩMUFA = mono-unsaturated fatty acid; ƩPUFA = poly-unsaturated fatty acid; Ʃn-3 = total omega 3 fatty acid; Ʃn-6 = total omega 6 fatty acid.
Effect of MLE, GEE and CFE supplementation on heart death receptor-dependent apoptotic pathway (Fas receptor, FADD, Caspase-8, BAK, C-Caspase-9, Cytochrome-c and Caspase-3) mRNA expression in AD mice.
| Enzyme | Enzyme/β-actin | ||||
|---|---|---|---|---|---|
| Control | AD | AD + MLE | AD + GEE | AD + CFE | |
| Fas receptor | 1.00 ± 0.15 b | 2.65 ± 0.15 a | 1.62 ± 0.18 c | 1.65 ± 0.28 c | 1.86 ± 0.13 c |
| FADD | 1.00 ± 0.13 b | 2.42 ± 0.13 a | 1.53 ± 0.15 c | 1.45 ± 0.12 c | 1.77 ± 0.28 c |
| Caspase-8 | 1.00 ± 0.08 b | 2.75 ± 0.08 a | 1.78 ± 0.27 c | 1.56 ± 0.18 c | 1.89 ± 0.16 c |
| BAK | 1.00 ± 0.07 b | 2.21 ± 0.07 a | 1.35 ± 0.16 c | 1.33 ± 0.19 c | 1.45 ± 0.08 c |
| C-Caspase-9 | 1.00 ± 0.09 b | 2.33 ± 0.09 a | 1.56 ± 0.38 c | 1.68 ± 0.17 c | 1.82 ± 0.28 c |
| Cytochrome- | 1.00 ± 0.19 b | 2.41 ± 0.89 a | 1.56 ± 0.37 c | 1.42 ± 0.35 c | 1.75 ± 0.33 c |
| Caspase-3 | 1.00 ± 0.32 b | 2.56 ± 0.89 a | 1.46 ± 0.21 c | 1.62 ± 0.28 c | 1.88 ± 0.19 c |
All the data showed here are the ratios of each enzyme to β-actin according to the quantitative and statistical results of reverse transcription-polymerase chain reaction (RT-PCR) from densitometric analysis. (a–c) Values represent mean ± SD (n = 8), and values different superscripts are significantly different (p < 0.05). AD, Alzheimer’s disease; MLE, Meretrix lusoria; GEE, Geloina eros; CFE, Corbicula fluminea.
Effect of MLE, GEE and CFE supplementation on heart survival pathway (p-IGF1R, p-PI3K p-AKT, Bcl-XL and Bcl2) mRNA expression in AD mice.
| Enzyme | Enzyme/β-actin | ||||
|---|---|---|---|---|---|
| Control | AD | AD + MLE | AD + GEE | AD + CFE | |
| p-IGF1R | 1.00 ± 0.21 b | 0.76 ± 0.13 c | 3.63 ± 0.36 a | 3.91 ± 0.55 a | 2.32 ± 0.88 a |
| p-PI3K | 1.00 ± 0.15 b | 0.58 ± 0.15 c | 3.37 ± 0.37 a | 2.75 ± 0.65 a | 1.63 ± 0.52 a |
| p-AKT | 1.00 ± 0.16 b | 0.35 ± 0.15 c | 2.55 ± 0.32 a | 2.83 ± 0.53 a | 1.82 ± 0.27 a |
| Bcl-XL | 1.00 ± 0.22 b | 0.25 ± 0.29 c | 1.32 ± 0.27 a | 1.36 ± 0.17 a | 1.25 ± 0.15 a |
| Bcl2 | 1.00 ± 0.11 b | 0.56 ± 0.31 c | 1.35 ± 0.12 a | 1.38 ± 0.13 a | 1.26 ± 0.13 a |
All the data showed here are the ratios of each enzyme to β-actin according to the quantitative and statistical results of RT-PCR from densitometric analysis. (a–c) Values represent mean ± SD (n = 8), and values different superscripts are significantly different (p < 0.05). AD, Alzheimer’s disease; MLE, Meretrix lusoria; GEE, Geloina eros; CFE, Corbicula fluminea.
Effect of MLE, GEE and CFE supplementation on heart SIRT1 pathway (p-AMPK-α, SIRT1, PGC1-α and p-FOXO3) mRNA expression in AD mice.
| Enzyme | Enzyme/β-actin | ||||
|---|---|---|---|---|---|
| Control | AD | AD + MLE | AD + GEE | AD + CFE | |
| p-AMPK-α | 1.00 ± 0.13 b | 2.56 ± 0.12 a | 1.23 ± 0.39 b | 1.33 ± 0.27 b | 1.23 ± 0.65 b |
| SIRT1 | 1.00 ± 0.22 b | 2.21 ± 0.23 a | 3.56 ± 0.65 b | 4.46 ± 0.52 b | 3.21 ± 0.53 b |
| PGC1-α | 1.00 ± 0.35 b | 2.65 ± 0.35 a | 1.33 ± 0.29 b | 1.43 ± 0.27 b | 1.31 ± 0.15 b |
| p-FOXO3 | 1.00 ± 0.16 b | 2.36 ± 0.27 a | 1.23 ± 0.19 b | 1.35 ± 0.25 b | 1.13 ± 0.33 b |
All the data showed here are the ratios of each enzyme to β-actin according to the quantitative and statistical results of RT-PCR from densitometric analysis. (a–c) Values represent mean ± SD (n = 8), and values different superscripts are significantly different (p < 0.05). AD, Alzheimer’s disease; MLE, Meretrix lusoria; GEE, Geloina eros; CFE, Corbicula fluminea.
Figure 1Apoptotic and survival pathway.
Composition of the experimental diets for animal diet.
| Ingredient | Diets | ||||
|---|---|---|---|---|---|
| Control | AD (%) | AD + MLE (%) | AD + GEE (%) | AD + CFE (%) | |
| Casein | 20 | 20 | 20 | 20 | 20 |
| Methionine | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 |
| Cellulose | 5 | 5 | 5 | 5 | 5 |
| Corn oil | 2 | 2 | 2 | 2 | 2 |
| Cholesterol | 2 | 2 | 2 | 2 | 2 |
| MLE | 0 | 0 | 6 | 0 | 0 |
| GEE | 0 | 0 | 0 | 6 | 0 |
| CFE | 0 | 0 | 0 | 0 | 6 |
| Choline | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 |
| Mineral mixa | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 |
| Vitamin mixb | 1 | 1 | 1 | 1 | 1 |
| Corn starch | 31 | 31 | 25 | 25 | 25 |
| Sucrose | 35 | 35 | 35 | 35 | 35 |
(a) Mineralsper 100 g diet: NaCl 7.4 g, K2C6H5O7·H2O 22g, K2SO4 5.2 g, CaHPO4 50 g, MgO 2.4 g, FeC6H5O7·5H2O 0.6 g, MnCO3 0.35 g, CuCO3 30 mg, CrK(SO4)2·12H2O 55 mg, CoCl2·6H2O 10 mg, KI 1 mg, ZnCO3 160 mg. (b) Vitamin per 100 g diet: thiamine 100 mg, riboflavin 150 mg, pyridoxine HCl 100mg, nicotinamide 1000 mg, d-panthenate 500 mg, folic acid 50 mg, vitamine B12 0.1 mg, vitamin A 2.5 × 105 IU, vitamin E 100 mg, calciferol 2 × 104 IU, vitamin C 3.7 × 103 mg.